Nutra Pharma Announces Provision Of RPI-78M Under Compassionate Release To Adrenomyeloneuropathy (AMN) Patients
In July, Nutra Pharma announced the completion of ReceptoPharm's Phase IIb/IIIa clinical study of RPI-78M for treating AMN. The last patient's visit occurred in August 2008 and currently, the data from the trial are being prepared for analysis, with results expected during early 2009.
"This is an exciting time for Nutra Pharma as we await the clinical findings from our recent study," said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "While the data from this trial is being reviewed and cleaned for analysis, we are pleased to be able to provide RPI-78M, under compassionate release to those patients who were enrolled in the trial and wish to remain on the drug," he added.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. The disorder is characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades.
There is currently no approved treatment for AMN. The disease's rarity designates it as an orphan drug candidate both in Europe and in the U.S.
"We want to complete the data quality control before the database is closed and the results are analyzed and before releasing the results from the trial," explained Paul Reid, CEO of ReceptoPharm. "We are planning for success and subject to favorable clinical data from the current trial, we are preparing to initiate a subsequent study and also preparing to request a meeting with the European regulatory agency to discuss licensing strategy," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Providing RPI-78M under compassionate release to patients enrolled in the Adrenomyeloneuropathy (AMN) clinical study should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at http://www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
NutraPharma.com. "Nutra Pharma Announces Provision Of RPI-78M Under Compassionate Release To Adrenomyeloneuropathy (AMN) Patients." Medical News Today. MediLexicon, Intl., 17 Nov. 2008. Web.
22 Feb. 2017. <http://www.medicalnewstoday.com/releases/129677.php>
NutraPharma.com. (2008, November 17). "Nutra Pharma Announces Provision Of RPI-78M Under Compassionate Release To Adrenomyeloneuropathy (AMN) Patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.